Zydus Lifesciences Beheer
Beheer criteriumcontroles 3/4
De CEO Zydus Lifesciences is Sharvil Patel, benoemd in Apr2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 300.00M, bestaande uit 60% salaris en 40% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.001% van de aandelen van het bedrijf, ter waarde ₹ 14.40M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.5 jaar en 7.3 jaar.
Belangrijke informatie
Sharvil Patel
Algemeen directeur
₹300.0m
Totale compensatie
| Percentage CEO-salaris | 60.0% |
| Dienstverband CEO | 7.6yrs |
| Eigendom CEO | 0.001% |
| Management gemiddelde ambtstermijn | 6.5yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹42b |
| Mar 31 2024 | ₹300m | ₹180m | ₹38b |
| Dec 31 2023 | n/a | n/a | ₹30b |
| Sep 30 2023 | n/a | n/a | ₹28b |
| Jun 30 2023 | n/a | n/a | ₹25b |
| Mar 31 2023 | ₹263m | ₹180m | ₹20b |
| Dec 31 2022 | n/a | n/a | ₹21b |
| Sep 30 2022 | n/a | n/a | ₹20b |
| Jun 30 2022 | n/a | n/a | ₹22b |
| Mar 31 2022 | ₹200m | ₹180m | ₹22b |
| Dec 31 2021 | n/a | n/a | ₹23b |
| Sep 30 2021 | n/a | n/a | ₹23b |
| Jun 30 2021 | n/a | n/a | ₹23b |
| Mar 31 2021 | ₹263m | ₹180m | ₹22b |
| Dec 31 2020 | n/a | n/a | ₹18b |
| Sep 30 2020 | n/a | n/a | ₹17b |
| Jun 30 2020 | n/a | n/a | ₹13b |
| Mar 31 2020 | ₹250m | ₹247m | ₹12b |
| Dec 31 2019 | n/a | n/a | ₹12b |
| Sep 30 2019 | n/a | n/a | ₹14b |
| Jun 30 2019 | n/a | n/a | ₹17b |
| Mar 31 2019 | ₹250m | ₹248m | ₹18b |
| Dec 31 2018 | n/a | n/a | ₹20b |
| Sep 30 2018 | n/a | n/a | ₹20b |
| Jun 30 2018 | n/a | n/a | ₹21b |
| Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Compensatie versus markt: De totale vergoeding ($USD 3.56M ) Sharvil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.09M ).
Compensatie versus inkomsten: De vergoeding van Sharvil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sharvil Patel (45 yo)
7.6yrs
Tenure
₹300,000,000
Compensatie
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 7.6yrs | ₹300.00m | 0.0015% ₹ 14.4m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 338.8m | |
| President & CEO of America | 1.1yrs | geen gegevens | geen gegevens | |
| Chief Financial Officer | no data | ₹54.31m | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Company Secretary & Compliance Officer | 5.8yrs | ₹2.09m | geen gegevens |
6.5yrs
Gemiddelde duur
Ervaren management: Het managementteam van ZYDUSLIFE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 27.3yrs | ₹300.00m | 0.0015% ₹ 14.4m | |
| COO & Executive Director | 7.3yrs | ₹140.00m | 0.035% ₹ 338.8m | |
| Non-Executive Chairman | 29.5yrs | ₹1.20m | 74.98% ₹ 734.3b | |
| Independent Director | 8.5yrs | ₹4.00m | geen gegevens | |
| Non-Executive Non-Independent Director | 27.3yrs | ₹4.00m | 0.0012% ₹ 11.4m | |
| Independent Non-Executive Director | 5.9yrs | ₹4.10m | geen gegevens | |
| Independent Director | 2yrs | ₹3.50m | geen gegevens | |
| Independent Director | 2yrs | ₹3.50m | geen gegevens | |
| Independent Director | less than a year | geen gegevens | 0.00044% ₹ 4.3m |
7.3yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ZYDUSLIFE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).